Core Viewpoint - The company, a global provider of life science tools and technology services, is set to go public on the Hong Kong Stock Exchange, having previously listed on the A-share market in 2021, with a current market capitalization of approximately 11.6 billion RMB [1]. Financial Performance - The company reported revenues of 645 million RMB and a net profit of 120 million RMB for 2024, with a gross margin of 84.77% [1]. - For the first nine months of 2025, the company achieved revenues of 613 million RMB and a net profit of 132 million RMB, reflecting a year-on-year revenue growth of 32.26% and a net profit growth of 66.66% [5]. - The gross margin for the first nine months of 2025 was 82.20%, while the net profit margin was 21.48% [5]. Market Position - According to Frost & Sullivan, the company ranks first among all domestic suppliers in China and third globally in the recombinant protein market, with a market share of approximately 2.5% [9][10]. - The global recombinant protein market is projected to grow from 1 billion USD in 2020 to 3 billion USD by 2024, with a compound annual growth rate (CAGR) of 31.9% [6]. Product and Service Offering - The company offers a comprehensive product portfolio that includes high-quality biological reagents, such as recombinant proteins, antibodies, and analytical test kits, along with various technical services [2]. - As of the latest date, the company provides over 5,000 product SKUs and diverse technical service combinations, all produced under strict international quality standards [2]. Client Base and Business Model - The company serves a diverse and high-quality client base, including major pharmaceutical companies and high-growth biotech firms, with a 100% repurchase rate from its top 20 clients [4]. - The company operates on a "dual-engine" business model in both China and the United States, providing lifecycle solutions across research, production, and clinical application stages [4]. Industry Overview - The recombinant protein market in China is expected to expand from 100 million USD in 2020 to 400 million USD by 2024, with a CAGR of 25.9% [6].

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is actively developing products related to monkeypox and has a strong focus on recombinant proteins and cell immunotherapy, benefiting from the depreciation of the RMB and being recognized as a "specialized, refined, distinctive, and innovative" enterprise [2][3][4]. Group 1: Company Performance - As of September 30, 2025, the company achieved a revenue of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit attributable to shareholders of 132 million yuan, with a year-on-year increase of 58.61% [9]. - The company's overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4]. - The main business revenue composition includes 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [8]. Group 2: Market Position and Recognition - The company has been included in the Ministry of Industry and Information Technology's list of national "specialized, refined, distinctive, and innovative" small giant enterprises, which signifies its strong innovation capability and market share in niche markets [3]. - The company is involved in various concept sectors, including monkeypox, Alzheimer's, cell immunotherapy, biomedicine, and artificial intelligence [9]. Group 3: Stock Performance and Trading Activity - On February 12, the company's stock rose by 0.94%, with a trading volume of 311 million yuan and a turnover rate of 4.78%, leading to a total market capitalization of 8.476 billion yuan [1]. - The average trading cost of the stock is 56.87 yuan, with recent buying activity observed, although the buying strength is not strong [7]. - The stock has a significant number of shareholders, totaling 10,600, with a decrease of 9.75% compared to the previous period [9].

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is actively developing products related to monkeypox and has a strong focus on recombinant proteins and cell immunotherapy, benefiting from the depreciation of the RMB and being recognized as a "specialized, refined, distinctive, and innovative" enterprise [2][3][4]. Group 1: Company Performance - On February 11, the company's stock rose by 1.43%, with a trading volume of 133 million yuan and a turnover rate of 2.11%, leading to a total market capitalization of 8.397 billion yuan [1]. - For the period from January to September 2025, the company achieved a revenue of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit attributable to shareholders of 132 million yuan, up 58.61% year-on-year [9]. - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan distributed over the past three years [9]. Group 2: Product Development and Market Position - The company has initiated the development of products in response to the monkeypox virus and has launched multiple recombinant proteins, antibodies, and test kits to support vaccine and therapeutic drug development [2]. - The company has developed high-quality recombinant proteins targeting various disease markers, which are essential for biopharmaceutical research and production [2]. - The company has introduced a specific antibody targeting the CD19 antigen, enhancing the detection methods for CAR-T cell therapy, and is expanding its product offerings related to cell and gene therapy [2]. Group 3: Market and Financial Insights - The company's overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4]. - The company is classified under the pharmaceutical and biotechnology sector, focusing on antigen detection, monkeypox concepts, Alzheimer's, and cell immunotherapy [9]. - As of September 30, the number of shareholders decreased by 9.75%, while the average number of circulating shares per person increased by 54.93% [9].

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is actively developing products related to monkeypox and has a strong focus on recombinant proteins and cell immunotherapy, benefiting from the depreciation of the RMB and its recognition as a "specialized and innovative" enterprise [2][3][4]. Group 1: Company Performance - On February 6, the company's stock rose by 0.18%, with a trading volume of 150 million yuan and a turnover rate of 2.39%, bringing the total market capitalization to 8.304 billion yuan [1]. - For the period from January to September 2025, the company achieved a revenue of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit attributable to shareholders of 132 million yuan, up 58.61% year-on-year [9]. - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan distributed over the past three years [9]. Group 2: Product Development and Market Position - The company has initiated the development of products related to monkeypox virus and has launched multiple recombinant proteins, antibodies, and test kits to support vaccine and therapeutic drug development [2]. - The company has developed high-quality recombinant proteins targeting various disease markers, fulfilling the needs of biopharmaceutical research and production [2]. - The company has introduced a specific antibody targeting the CD19 antigen, enhancing the detection methods for CAR-T cell therapy, and is expanding its product offerings related to cell and gene therapy [2]. Group 3: Industry Recognition and Financial Impact - The company has been recognized as a national-level "specialized and innovative" small giant enterprise, which signifies its strong market position and innovation capabilities [3]. - The company's overseas revenue accounted for 66.46% of its total revenue, benefiting from the depreciation of the RMB [4]. - The company operates in the pharmaceutical and biotechnology sector, focusing on antigen detection, monkeypox, Alzheimer's, and cell immunotherapy [9].

Group 1 - The core point of the news is that Baipusi has experienced a significant decline in its stock price, dropping 5.1% to 52.81 yuan per share, with a total market value of 8.829 billion yuan and a cumulative drop of 19.75% over four consecutive days [1] - Baipusi Biotechnology Co., Ltd. is located in Beijing and was established on July 22, 2010, with its IPO on October 18, 2021. The company specializes in providing key biological reagent products and technical services, with its main business revenue composition being 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [1] Group 2 - From the perspective of major fund holdings, one fund under Jiao Yin Schroder has a significant position in Baipusi. The Jiao Yin Medical Innovation Stock A fund held 1.5937 million shares, accounting for 4.37% of the fund's net value, making it the fifth-largest holding. The estimated floating loss today is approximately 4.5262 million yuan, with a total floating loss of 21.8343 million yuan during the four-day decline [2] - The Jiao Yin Medical Innovation Stock A fund was established on March 23, 2017, with a latest scale of 1.9 billion yuan. Year-to-date returns are 1.01%, ranking 4796 out of 5580 in its category, while the one-year return is 24.72%, ranking 3014 out of 4286. Since inception, the fund has achieved a return of 162.82% [2] - The fund manager of Jiao Yin Medical Innovation Stock A is Lou Huiyuan, who has been in the position for 7 years and 146 days, with the best fund return during this period being 129.49% and the worst being -24.1% [2]

Core Viewpoint - Yiqiao Shenzhou's stock price experienced a slight decline of 0.17% on January 29, with a trading volume of 97.49 million yuan, indicating a mixed market sentiment towards the company [1]. Financing Summary - On January 29, Yiqiao Shenzhou had a financing buy-in amount of 8.13 million yuan and a financing repayment of 11.76 million yuan, resulting in a net financing outflow of 3.64 million yuan [1]. - The total financing and securities balance for Yiqiao Shenzhou reached 258 million yuan, with the financing balance accounting for 2.80% of the circulating market value, which is above the 60th percentile of the past year [1]. - The company had a low short-selling balance of 709,800 yuan, indicating a lower level of short-selling activity compared to the past year [1]. Business Performance - As of January 9, Yiqiao Shenzhou had 19,600 shareholders, reflecting a 1.43% increase, while the average circulating shares per person decreased by 1.41% to 6,100 shares [2]. - For the period from January to September 2025, Yiqiao Shenzhou reported a revenue of 511 million yuan, representing a year-on-year growth of 10.00%, and a net profit attributable to shareholders of 110 million yuan, with a growth of 10.94% [2]. Dividend Information - Since its A-share listing, Yiqiao Shenzhou has distributed a total of 1.802 billion yuan in dividends, with 1.122 billion yuan distributed over the past three years [3]. - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, increasing its holdings by 200,200 shares to 919,600 shares [3].

Group 1 - The core viewpoint of the news is that Baipusais has shown significant financial performance with a notable increase in revenue and net profit, alongside active trading activity in its stock [2][3] - As of January 29, Baipusais' stock price decreased by 1.15%, with a trading volume of 194 million yuan, and a net financing buy of -4.85 million yuan [1] - The company has a financing balance of 108 million yuan, which is 1.11% of its market capitalization, indicating a high level of financing activity compared to the past year [1] Group 2 - For the period from January to September 2025, Baipusais achieved an operating income of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit attributable to shareholders of 132 million yuan, up 58.61% year-on-year [2] - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders decreased by 9.75% to 10,600, while the average circulating shares per person increased by 54.93% to 11,947 shares [2]

Market Performance - A-shares showed a slight increase with the Shanghai Composite Index up 0.18% to 4139.9 points, and the Shenzhen Component Index up 0.09%[1] - The Hang Seng Index rebounded, rising 1.35% to 27126.95 points, with the Hang Seng Technology Index up 0.5% and the Hang Seng China Enterprises Index up 1.07%[1] - The total market turnover in Hong Kong was 2543.726 billion HKD[1] Currency and Federal Reserve Insights - Trump downplayed concerns over the dollar's depreciation, leading to a significant drop in the dollar index, with the euro rising above 1.20 against the dollar[1][12] - The Federal Reserve is expected to pause its interest rate cuts, indicating a potential consensus on policy direction[1][12] Economic Sentiment - A survey by the People's Bank of China revealed that more households are looking to increase savings and reduce spending compared to before the latest round of the US-China trade war, reflecting a more pessimistic outlook on income[8][12] - The market is closely monitoring the Federal Reserve's interest rate decision, with expectations of no changes this week[12]

Company Overview - Beijing Baipusi Biotechnology Co., Ltd. (Baipusi) has submitted its listing application to the Hong Kong Stock Exchange, with CMB International as its sole sponsor [1] - Baipusi is a leading player in the biological reagent industry, particularly in the recombinant protein segment, ranking first among domestic suppliers in China and third globally by revenue in 2024 [1][3] - The company offers a comprehensive product portfolio that includes high-quality biological reagents and various technical services, supporting the entire value chain of biopharmaceutical companies from R&D to clinical applications [3][5] Financial Performance - For the fiscal year 2023, Baipusi reported revenues of approximately RMB 544 million, with projected revenues of RMB 645 million for 2024 and RMB 613 million for the nine months ending September 30, 2025 [6][10] - The gross profit for 2023 was around RMB 459 million, with a gross margin of 84.3%, and is expected to maintain a gross margin of approximately 82.2% in 2025 [8][10] - The company recorded a profit of approximately RMB 148 million for 2023, with a projected profit of RMB 132 million for the nine months ending September 30, 2025 [10][11] Market Overview - The global life sciences tools market reached USD 32.1 billion in 2020 and is projected to grow at a CAGR of 5.2% to USD 39.3 billion by 2024, further expanding to USD 61 billion by 2030 [12] - The biological reagent market, which includes products and services, was valued at USD 18.2 billion in 2020, with expectations to grow to USD 25.1 billion by 2024, and USD 35.6 billion by 2030 [14][16] - The recombinant protein market is anticipated to grow from USD 1 billion in 2020 to USD 3 billion by 2024, with a CAGR of 31.9%, and further to USD 7.8 billion by 2030 [18][19] Business Model - Baipusi operates on a "dual-engine" business model in China and the United States, allowing it to acquire advanced technological knowledge and efficient production capabilities [5] - The company serves a diverse clientele, including the top 20 global pharmaceutical companies and the top five life sciences service providers, with a 100% repurchase rate from its top clients [5][6] - Baipusi's production facilities in Beijing and Suzhou comply with international quality standards, including ISO certifications and GMP [6]

| 编纂 的[编纂]數目 :: | [编纂]股H股(視乎[编纂]行使與否而定) | | --- | --- | | [编纂]數目 : | [编纂]股H股(可予重新分配) | | [编纂]數目 : | [編纂]股H股(可予重新分配及視乎[編纂]行使與否 | | | 定) | | 最高[編纂] : 每股H股[编纂]港元,另加1.0%經紀佣金、0.0027% | | | | 證監會交易徵費、0.00565%的聯交所交易費以 | | | 及0.00015%的會財局交易徵費(須於申請時以港 | | | 元繳足,可予退還) | | 面值 | 每股H股人民幣1.00元 | | 股份代號 : [·] | | 智通财经APP获悉，据港交所1月26日披露，北京百普赛斯生物科技股份有限公司(简称：百普赛斯， 301080.SZ)向港交所主板递交上市申请书，招商证券国际为其独家保荐人。招股书显示，百普赛斯是全 球生命科学工具及技术服务提供商，致力于赋能生物制药公司覆盖研发、生产及临床应用的全价值链。 根据弗若斯特沙利文的资料，在全球重组蛋白市场中，按2024年收入计，公司在所有中国本土供应商中 排名第一，在全球所有供应商中排名第三。 ...